Resource impact statement
Cancer Drugs Fund technology
NICE has recommended avelumab with axitinib for use within the Cancer Drugs Fund as an option for untreated advanced renal cell carcinoma in adults.
Avelumab with axitinib will be available to the NHS in line with the managed access agreement with NHS England. As part of this, there is a commercial access agreement that makes avelumab (Bavencio, Merck Europe BV) with axitinib (Inlyta, Pfizer) available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of avelumab with axitinib will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires, July 2023, or when the results of the managed access agreement data collection are available, whichever is sooner. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) – a new deal for patients, taxpayers and industry.
It is estimated that around 1,600 people per year with untreated advanced renal cell carcinoma are eligible for treatment with avelumab with axitinib.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: